Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

295 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial.
Keller J, Bartolucci A, Carpenter JT Jr, Feagler J. Keller J, et al. Cancer Treat Rep. 1986 Oct;70(10):1221-3. Cancer Treat Rep. 1986. PMID: 3530448 Clinical Trial.
Gallium nitrate was administered as a 700-mg/m2 iv bolus infusion over 15-30 minutes every 2 weeks to 138 patients with malignant lymphoproliferative diseases. ...As a single agent, bolus gallium nitrate has little activity in lymphoproliferative diseases....
Gallium nitrate was administered as a 700-mg/m2 iv bolus infusion over 15-30 minutes every 2 weeks to 138 patients with malignant lym …
A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates.
Wallack MK, McNally KR, Leftheriotis E, Seigler H, Balch C, Wanebo H, Bartolucci AA, Bash JA. Wallack MK, et al. Cancer. 1986 Feb 1;57(3):649-55. doi: 10.1002/1097-0142(19860201)57:3<649::aid-cncr2820570342>3.0.co;2-6. Cancer. 1986. PMID: 3943002
Vaccinia melanoma oncolysates (VMO) were tested in a Southeastern Cancer Study Group (SECSG) Phase I/II trial. Forty-eight patients with high-risk Stage I or pathologic Stage II disease were placed on study at six different dose levels and two different treatment regimens. …
Vaccinia melanoma oncolysates (VMO) were tested in a Southeastern Cancer Study Group (SECSG) Phase I/II trial. Forty-eight patients w …
Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial.
Gams RA, Rainey M, Dandy M, Bartolucci AA, Silberman H, Omura G. Gams RA, et al. J Clin Oncol. 1985 Sep;3(9):1188-95. doi: 10.1200/JCO.1985.3.9.1188. J Clin Oncol. 1985. PMID: 3897470 Clinical Trial.
A total of 296 evaluable patients with unfavorable categories of malignant lymphoma were randomly assigned treatment with cyclophosphamide, vincristine, and prednisone plus BCNU (BCOP) or doxorubicin (CHOP). ...CHOP appears preferable for diffuse large-cell categories, sin
A total of 296 evaluable patients with unfavorable categories of malignant lymphoma were randomly assigned treatment with cyclophosph
Phase II evaluation of diaziquone in gastric and pancreatic cancers. A Southeastern Cancer Study Group Trial.
DeSimone P, Kramer B, Omura GA, Bartolucci AA. DeSimone P, et al. Am J Clin Oncol. 1986 Oct;9(5):401-2. doi: 10.1097/00000421-198610000-00008. Am J Clin Oncol. 1986. PMID: 3776902
Since only 10 chemotherapy-naive patients were treated in each disease category, we do not regard this as a definitive trial, but our experience suggests that this dose schedule is not likely to be useful in these types of cancer....
Since only 10 chemotherapy-naive patients were treated in each disease category, we do not regard this as a definitive trial, but our …
Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R, Greco FA. Luedke DW, et al. J Clin Oncol. 1990 May;8(5):886-91. doi: 10.1200/JCO.1990.8.5.886. J Clin Oncol. 1990. PMID: 2159054 Clinical Trial.
A total of 435 patients were enrolled in the trial, with 410 (94%) assessable for prognostic characteristics and survival. Among the 375 patients assessable for response, only 58 (15%) achieved objective response. ...In a prognostic factor analysis, treatment was no
A total of 435 patients were enrolled in the trial, with 410 (94%) assessable for prognostic characteristics and survival. Among the
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PL. Vogler WR, et al. J Clin Oncol. 1992 Jul;10(7):1103-11. doi: 10.1200/JCO.1992.10.7.1103. J Clin Oncol. 1992. PMID: 1607916 Clinical Trial.
PURPOSE: A randomized clinical trial was undertaken to compare the therapeutic effectiveness of idarubicin (IDR) to daunorubicin (DNR), and both were given in combination with cytarabine (CA) in acute myelogenous leukemic (AML) patients. PATIENTS AND METHODS: Newly diagnos …
PURPOSE: A randomized clinical trial was undertaken to compare the therapeutic effectiveness of idarubicin (IDR) to daunorubicin (DNR …
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR, Weiner RS, Moore JO, Omura GA, Bartolucci AA, Stagg M. Volger WR, et al. Leukemia. 1995 Sep;9(9):1456-60. Leukemia. 1995. PMID: 7544851 Clinical Trial.
Patients with untreated leukemia between the ages of 15 and 50 were given daunorubicin 45 mg/m2 for the first 3 days of a 10-day continuous infusion of cytosine arabinoside, initially at a dose of 2000 mg/m2 but reduced to 100 mg/m2 because of toxicity. Those under …
Patients with untreated leukemia between the ages of 15 and 50 were given daunorubicin 45 mg/m2 for the first 3 days of a 10-day cont …
Weekly mitoxantrone therapy of Hodgkin's disease, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. A Southeastern Cancer Study Group Trial.
Keller JW, Omura GA, Gams RA, Bartolucci AA. Keller JW, et al. Am J Clin Oncol. 1987 Jun;10(3):194-5. doi: 10.1097/00000421-198706000-00002. Am J Clin Oncol. 1987. PMID: 3591737
A weekly schedule of mitoxantrone was evaluated in chronic lymphoproliferative disorders. One of 11 patients with Hodgkin's disease, 2 of 12 with favorable-histology non-Hodgkin's lymphoma, 4 of 27 with unfavorable-histology non-Hodgkin's lymphoma, and 1 of 11 with chronic
A weekly schedule of mitoxantrone was evaluated in chronic lymphoproliferative disorders. One of 11 patients with Hodgkin's disease,
Subcategories of histiocytic lymphoma: associations with survival and reproducibility of classification. The Southeastern Cancer Study Group experience.
Whitcomb CC, Cousar JB, Flint A, Crissman JD, Bartolucci AA, Durant JR, Gams RA, Collins RD, Byrne GE Jr. Whitcomb CC, et al. Cancer. 1981 Dec 1;48(11):2464-74. doi: 10.1002/1097-0142(19811201)48:11<2464::aid-cncr2820481120>3.0.co;2-4. Cancer. 1981. PMID: 7028247
The cases within the three follicular center cell categories, considered collectively, had a significantly better survival than did the cases within the other three categories considered as a whole. The pathologists classified cases generally as being of a fo …
The cases within the three follicular center cell categories, considered collectively, had a significantly better survival than did t …
295 results
Jump to page
Feedback